Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus-Reference-Cited by-同舟云学术

Overview of clinically approved oral antidiabetic agents for the treatment of type 2 diabetes mellitus

Published:2015-01-12 Issue:2 Volume:42 Page:125-138
ISSN:0305-1870
Container-title:Clinical and Experimental Pharmacology and Physiology
language:en
Short-container-title:Clin Exp Pharmacol Physiol

Author:

He Zhi-Xu¹,Zhou Zhi-Wei²,Yang Yinxue³,Yang Tianxin⁴,Pan Si-Yuan⁵,Qiu Jia-Xuan⁶,Zhou Shu-Feng²

Affiliation:

1. Guizhou Provincial Key Laboratory for Regenerative Medicine; Stem Cell and Tissue Engineering Research Center & Sino-US Joint Laboratory for Medical Sciences; Guiyang Medical University; Guiyang China

2. Department of Pharmaceutical Sciences; College of Pharmacy; University of South Florida; Tampa FL USA

3. Department of Colorectal Surgery; General Hospital of Ningxia Medical University; Yinchuan China

4. Department of Internal Medicine; University of Utah and Salt Lake Veterans Affairs Medical Center; Salt Lake City UT USA

5. Department of Chinese Medicinal Pharmacology; School of Chinese Materia Medica; Beijing University of Chinese Medicine; Beijing China

6. Department of Oral and Maxillofacial Surgery; The First Affiliated Hospital of Nanchang University; Nanchang China

Funder

College of Pharmacy, University of South Florida

Guizhou Medical University

Publisher

Wiley

Subject

Physiology (medical),Pharmacology,Physiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/1440-1681.12332/fullpdf

Reference100 articles.

1. Type 2 diabetes mellitus in 2012. Optimal management of T2DM remains elusive;Holman;Nat. Rev. Endocrinol.,2013

2. A review of the efficacy and safety of oral antidiabetic drugs;Stein;Expert Opin. Drug Saf.,2013

3. Aldose reductase inhibitors;Oka;J. Enzyme Inhib.,2001

4. N-[5-(Trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-N-methylglycine (tolrestat), a potent, orally active aldose reductase inhibitor;Sestanj;J. Med. Chem.,1984

5. Worldwide pharmacovigilance systems and tolrestat withdrawal;Foppiano;Lancet,1997

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparing the effects of biguanides and dipeptidyl peptidase-4 inhibitors on cardio-cerebrovascular outcomes, nephropathy, retinopathy, neuropathy, and treatment costs in diabetic patients;PLOS ONE;2024-08-09

2. Synthesis, characterization, DNA interaction, molecular docking, and α‐glucosidase inhibition studies of 3‐(pyrimidin‐2‐ylthio) groups substituted water soluble zinc (II) phthalocyanine;Applied Organometallic Chemistry;2024-06-17

3. Synthetic Approaches to Gliflozins: A Comprehensive Overview;Synthesis;2024-01-09

4. Advancing diabetes treatment: novel formulation of polydatin long-circulating liposomes and their glucose-regulating impact on hyperlipidemia-induced type 2 diabetic mice;Materials Advances;2024

5. Virtual Screening of 5-Benzylthiazolidine-2,4-Dione Derivatives in Search of Potent Ppar-Gamma Agonist;2024